ArticlePloS one2017

Cost-effectiveness of cetuximab and panitumumab for chemotherapy-refractory metastatic colorectal cancer.

Adriana Camargo Carvalho et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.